We report interim results of a multicenter registry study of patients with thyroid nodules indeterminate by cytology that underwent combined mutation (ThyGenX®) and microRNA (ThyraMIR®) testing in clinical practice. We examined the likelihood at which patients avoided surgery and survived without developing malignancy given combined test results.
Outcomes of patients with thyroid nodules clinically tested using a combination of mutation and microRNA classification: Interim results of a clinical experience study
ATA 2018 Washington DC
Patient management decisions are based on the independent medical judgment of the physician and molecular test results should be taken into consideration in conjunction with all relevant imaging, clinical findings, patient and family history, as well as patient preference.